Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2008 June;99(3) > Minerva Medica 2008 June;99(3):335-40





A Journal on Internal Medicine

Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236




Minerva Medica 2008 June;99(3):335-40

language: English

What sense in cannabinoid use as regulated by italian dm 18/04/07? pharmacological and giuridical considerations

Molinelli A. 1, Grossi S. 2, Bonsignore A. 1, Martelli A. 2

1 Dipartimento di Medicina Legale, del Lavoro Psicologia Medica e Criminologia Sezione di Medicina Legale Università degli Studi di Genova, Genova
2 Dipartimento di Medicina Interna Sezione di Farmacologia Università degli Studi di Genova, Genova


The present article relates to the Italian Ministerial Decree (DM) 18/04/2007 referring to what was established by the Financial Law 2007 on the matter of the use of drugs for the so called “off-label” uses. This law introduces three cannabinoid substances, with the common name of Delta 9 and Trans-delta 9 tetrahydrocannabinol and Nabilone, within the possible therapies for the treatment of “severe pain”. The authors underline the absence of a sufficient pharmacokinetical and pharmacodynamical knowledge supporting the use of cannabinoid substances in the “severe pain” therapy. Further more the professional prescriber could go against judicial conseguences if the drugs causes as verified the onset of collateral effects even severe that, for the scientific knowledge in possess at the present state, the authors know could take place.

top of page

Publication History

Cite this article as

Corresponding author e-mail